The company's platform is based on research from UC Berkeley and uses enzyme activation of native amino acids to fuse proteins together, allowing for the creation of novel therapeutics in oncology, autoimmune disorders, and vaccine development. Catena's technology differentiates itself from competitors by attaching natural amino acids tyrosine and cysteine, resulting in faster and more selective protein attachment. As a seed-stage company, Catena Biosciences is poised to disrupt the biotech industry with its innovative approach to protein conjugation.